Akebia Therapeutics Announces Second Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/24/2026
- S&P 500 ends marginally lower as investors focus on US-Iran war
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oil gains on little sign of progress in US-Iran talks
- S&P 500 history shows strong gains across Fed hiking cycles: BCA
- JPMorgan upgrades CoreWeave on stronger compute pricing
- Plug Power COO resigns to join another company
- Bloom Energy falls as Oracle invokes force majeure on AI project
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oracle Sends Force Majeure Notice Over New Mexico Data Center - Bloomberg
- Akamai signs $11.6B deal with Anthropic, up to $20B potential
Akebia Therapeutics (AKBA) PT Lowered to $18 at Needham & Company
August 9, 2018 1:40 PM EDTNeedham & Company lowered its price target on Akebia Therapeutics (NASDAQ: AKBA) to $18.00 (from $20.00) while maintaining a Buy rating.
Analsyt Chad Messer notes vadadustat pivotal readouts were pushed out. "We continue to expect that INNO2VATE will be fully enrolled by YE:18; however,... More
